Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Immutep S.A.

October 3, 2014
Immutep announces proposed acquisition by Prima BioMed Ltd
Immutep SA (“Immutep”), a late stage private biopharmaceutical company in the rapidly growing field of immuno-oncology, announces today it has reached an agreement by which it will be acquired (“Acquisition”) by Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”). More

January 6, 2011
Immutep and GlaxoSmithKline sign licence agreement for IMP731
Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases. More

September 7, 2010
Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer
Clinical research paper describes IMP321’s potency in achieving clinical benefit in 90 per cent of patients, combined with paclitaxel in first-line metastatic breast cancer. More

January 4, 2010
Immutep announces final results in phase I/II chemoimmunotherapy trial in breast cancer
ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer. More

October 6, 2009
Immutep announces new interim results in Phase I/II chemoimmunotherapy trial in breast cancer
New results confirm that ImmuFact IMP321 doubles clinical response rate. More

September 29, 2009
Immutep announces final results in advanced renal cell carcinoma
Clinical research paper describes IMP321's potency in inducing progression-free survival improvement and effector memory T cells. More

October 16, 2008
Immutep announces IND allowance in pancreatic cancer
A Phase I clinical trial of ImmuFact IMP321 in pancreatic cancer will be carried out at Washington University in Saint Louis (MO) More

June 25, 2008
Immutep reports that LAG-3 enhances activity of a cellular cancer immunotherapy in preclinical ...
Immutep reports that LAG-3 enhances activity of a cellular cancer immunotherapy in preclinical studies More

November 28, 2007
Immutep announces positive interim results from a study of ImmuFact IMP321 in metastatic breast ...
Immutep S.A announced positive interim results from a Phase I/II study of its lead product, ImmuFact(R) IMP321 in patients with metastatic breast cancer (MBC). More

September 17, 2007
Immutep announces that ImmuFact IMP321 induces activation of a wide range of human effector cyto...
Immutep S.A., a biopharmaceutical company specialised in immunostimulatory and immunomodulatory treatments of cancer and infectious or autoimmune disease, announced today the publication of a research paper showing that its lead product, IMP321, induces activation of a wide range of human effector cytotoxic cells. More

August 28, 2007
Immutep's ImmuFact IMP321 enters phase I trial in metastatic melanoma
Immutep S.A., a biopharmaceutical company specialised in immunostimulatory and immunomodulatory treatments of cancer and infectious or autoimmune disease, announced today that its lead product, ImmuFact(R) IMP321, has entered a Phase I clinical trial in metastatic melanoma in a novel protocol combining adoptive T cell transfer after transient lymphodepletion associated with peptide vaccination. More

Data


26,140
Tech investments
From our Online Data Service
16,888
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12N/AKnowledge management
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.